HPLC Method Development in One and a Half Days using the Selectivity Concept
Modern HPLC technologies such as UHPLC, monolithic silica or Fused-Core® particles provide a superior separation efficiency and resolution of peaks. But in general resolution is more strongly impacted by selectivity which can be changed most strongly by different stationary bonded phases. This presentation will discuss the choice of RP HPLC column chemistries such as RP-Amide, Phenyl, Pentafluorophenyl (F5) or Cyano that are available to provide alternative selectivities to traditional C18. It will compare their different retention mechanisms and highlight an approach to develop HPLC method within 1.5 days.
Key learnings of this webinar are:
Everybody doing HPLC Method Development and users of HPLC
Dr. Frank Michel
Analytical & Chromatography Scientific Advisor
Frank Michel developed, optimized and evaluated new stationary phases for HPLC in his Ph.D. at University in Muenster/Germany. His first business position was at Bernina Biosystems, a biopharmaceutical company, as Analytical Chemist for HPLC Method Development and Validation for Active Pharmaceutical Ingredients (APIs) and drug formulations.
Later he changed to Merck in different roles in Analytical and Chromatography. His next position was at HWI Analytik, an analytical service provider for the pharmaceutical industry. Frank returned in 2010 to Merck to continue his career as Analytical & Chromatography Technology Specialist. Five years later he advanced as Scientific Advisor for Analytical Technologies to support Asia-Pacific region.
Frank is a member of the Separation Science working group in the German Chemist Society (GDCh) as well as the Scientific Advisory Board of Analytix conference.
Research. Development. Production.
We are a leading supplier to the global Life Science industry with solutions and services for research, biotechnology development and production, and pharmaceutical drug therapy development and production.